Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Melatonin prevents early pituitary dysfunction induced by sucrose-rich diets.

Journal of pineal research | 2019

While physiological levels of glucocorticoids are required to ensure proper functions of the body, consistently high levels may engender several deleterious consequences. We have previously shown an increase in the activity of the hypothalamic-pituitary-adrenal (HPA) axis in rats fed sucrose-rich diets (SRD). The main goal of this study was to analyze the processes involved in the modulation of the pituitary production of ACTH by SRD, and to test melatonin as a possible therapeutic agent for the prevention of the HPA axis dysfunction. Male Wistar rats were fed standard chow and either SRD (30% sucrose in the drinking water) or plain water for three weeks. Melatonin was administered as subcutaneous pellets. Results showed that SRD treatment induced an increase in systemic ACTH and corticosterone levels and a decrease in melatonin levels. In the pituitary gland, we also detected an increase in the expression levels of proopiomelanocortin (POMC) that was accompanied by increased levels of: lipoperoxides, nitro-tyrosine modified proteins, catalase, heme oxygenase-1, interleukin-1β mRNA, and by an increase in the tissue number of inflammatory cells (F4/80 and Iba-1 positive cells). Melatonin treatment prevented all these systemic and pituitary changes as well as the increase in POMC expression induced by incubation of AtT-20 corticotrophs with conditioned media obtained from stimulated macrophages. In conclusion, stimulation of POMC/ACTH production in rats fed a SRD could involve the generation of oxidative stress and inflammation in the pituitary gland. Melatonin treatment prevented these effects and normalized the activity of the HPA axis.

Pubmed ID: 30586198 RIS Download

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


ACTH (SPM333) (antibody)

RRID:AB_831670

This monoclonal targets POMC

View all literature mentions

F4/80 (M-300) (antibody)

RRID:AB_2246477

This polyclonal targets F4 / 80

View all literature mentions

HO-1, pAb (antibody)

RRID:AB_10614948

This polyclonal targets HO-1 pAb

View all literature mentions

Iba1 antibody (antibody)

RRID:AB_2224402

This polyclonal targets AIF1

View all literature mentions

Goat Anti-Rabbit IgG (H + L)-HRP Conjugate (antibody)

RRID:AB_11125142

This polyclonal secondary targets IgG (H+L)

View all literature mentions

β-Actin Antibody (C4) (antibody)

RRID:AB_2714189

This monoclonal targets β-Actin

View all literature mentions

ACTH (SPM333) (antibody)

RRID:AB_831670

This monoclonal targets POMC

View all literature mentions

Goat Anti-Rabbit IgG (H + L)-HRP Conjugate (antibody)

RRID:AB_11125142

This polyclonal secondary targets IgG (H+L)

View all literature mentions

β-Actin Antibody (C4) (antibody)

RRID:AB_2714189

This monoclonal targets β-Actin

View all literature mentions

F4/80 (M-300) (antibody)

RRID:AB_2246477

This polyclonal targets F4 / 80

View all literature mentions

HO-1, pAb (antibody)

RRID:AB_10614948

This polyclonal targets HO-1 pAb

View all literature mentions

Iba1 antibody (antibody)

RRID:AB_2224402

This polyclonal targets AIF1

View all literature mentions

ACTH (SPM333) (antibody)

RRID:AB_831670

This monoclonal targets POMC

View all literature mentions